Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy for lymphoma

J D Shepherd1, G L Phillips

  • 1Vancouver General Hospital, Canada.

Current Opinion in Oncology
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Patients with refractory Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given.

Leukemia·2025
Same author

A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.

Leukemia·2024
Same author

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bone marrow transplantation·2015
Same author

Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study.

Bone marrow transplantation·2010
Same author

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.

Bone marrow transplantation·2009
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Modern chemoradiotherapy has improved cure rates for Hodgkin's disease and non-Hodgkin's lymphoma.
  • Patients refractory to initial treatments face poor prognoses.
  • High-dose therapy with hematopoietic stem cell support is a viable option for refractory lymphoma patients.

Purpose of the Study:

  • To review the application of high-dose therapy for lymphoma patients.
  • To explore methods for predicting patient benefit from this intensive treatment.
  • To discuss strategies for mitigating high-dose therapy toxicity.

Main Methods:

  • Review of current literature on high-dose therapy for lymphoma.
  • Analysis of predictive factors for treatment success.
  • Examination of supportive care measures to reduce toxicity.

Related Experiment Videos

Main Results:

  • Identified patterns in the utilization of high-dose therapy.
  • Highlighted key indicators for patient selection.
  • Summarized ancillary interventions for toxicity management.

Conclusions:

  • High-dose therapy with stem cell support offers a critical treatment avenue for refractory lymphoma.
  • Careful patient selection and toxicity management are essential for successful outcomes.
  • Further research into predictive markers and supportive care is warranted.